207, Porter St

Boston,

MA,

USA,

ZIP: 02128

Phone: +16174554188

The second edition of the industry-led Wet AMD and DME Drug Development Summit arrives in Boston to give you comprehensive insight into the current and emerging angiogenesis- inflammatory-directed and anti-fibrotic drug development programs for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and diabetic macular edema (DME).

Join this dedicated industry forum to network online and learn from senior leaders of discovery, translational sciences, and clinical development from the likes of Roche, Genentech, Novartis, Apellis, Outlook Therapeutics and more, to address the specific challenges for the biopharmaceutical and biotechnology in its efforts to bring long-lasting treatments which reduce clinical burden and can be commercialized to become the new standard-of-care in this vast ophthalmology indication.

Navigate across 3 jam-packed days including two interactive workshops exploring the optimization of administration techniques and viral and non-viral vectors to deliver safe and durable anti-angiogenic therapies to the eye and developing preclinical and translational models to predict human disease and efficacy of a drug.

Earlybird and group booking discounts available, visit the website for more information.

URLs:
Tickets: https://go.evvnt.com/988131-2?pid=1052
Brochure: https://go.evvnt.com/988131-3?pid=1052

Prices:
Pharma and Biotech Pricing - Conference + 2 Workshops: USD 4297.0,
Pharma and Biotech Pricing - Conference + 1 Workshop: USD 3648.0,
Pharma and Biotech Pricing - Conference Only: USD 2999.0,
Academic Pricing - Conference + 2 Workshops: USD 3697.0,
Academic Pricing - Conference + 1 Workshop: USD 3148.0,
Academic Pricing - Conference Only: USD 2599.0,
Solution Provider Pricing - Conference + 2 Workshops: USD 5097.0,
Solution Provider Pricing - Conference + 1 Workshop: USD 4348.0,
Solution Provider Pricing - Conference Only: USD 3599.0

Peter Kaiser, Professor of Opthalmology, Cleveland Clinic, Eliot Lazar, President, Medical Doctor, eLCON Medical, Stefan Scheidl, Franchise Head, Disease Area Ophthalmology, Global Medical Affairs, Roche, Parisa Zamiri, Chief Medical Officer, Graybug Vision, Carlos Quezada-Ruiz, Senior Medical Director Ophthalmology, Clinical Science, PDS Clinical Science Team Leader, Genentech, David Lally, Vitreoretinal Surgeon and Clinical Investigator, New England Retina Associates, Kerrie Brady, Chief Executive Officer, OcuTerra, Thomas Ciulla, Chief Medical and Development Officer, Clearside Bio, Lukas Scheibler, Chief Innovation Officer, Apellis, Mina Sooch, Chief Executive Officer, Ocuphire, David Tanzer, Chief Medical Officer, OcuTerra, Victor Chong, MD, Vice President , Global Head of Retina, Janssen R and D, Russ Trenary, President and Chief Executive Officer, Outlook Therapeutics, Amir Shojaei, Chief Scientific Officer, AsclepiX Therapeutics, Maria Gemenetzi, Global Drug Development, CD and A, Novartis Pharmaceuticals Ltd, Zhichao Wu, Principal Investigator, Centre for Eye Research Australia, Konstantinos Balaskas, Consultant Ophthalmologist and Medical Retina Specialist, Director, Moorfields Ophthalmic Reading Centre and Clinical AI Lab, Marion Munk, Chief Medical Officer, Isarna Therapeutics, Sungjin Lee, Principal Scientist, Surrozen, Daniel Chung, Chief Medical Officer,SparingVision, Stephen Poor, Director External Innovation and Translational Biomarkers, Novartis Institutes for Biomedical Research, Department of Ophthalmology, Eric Nelson, Senior Business Development Consultant US, HealthVest, LLC, Robert Dempsey, Chief Executive Officer, AsclepiX Therapeutics, Eric Ng, Assistant Professor of Ophthalmology, Harvard Medical School, Stephen Pakola, Chief Medical Officer, REGENXBIO